Unknown

Dataset Information

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.


ABSTRACT: Although tyrosine kinase inhibitors (TKIs) have revolutionized cancer therapy in the past two decades, severe drawbacks such as strong adverse effects and drug resistance limit their clinical application. Prodrugs represent a valuable approach to overcoming these disadvantages by administration of an inactive drug with tumor-specific activation. We have recently shown that hypoxic prodrug activation is a promising strategy for a cobalt(III) complex bearing a TKI of the epidermal growth factor receptor (EGFR). The aim of this study was the optimization of the physicochemical properties and enhancement of the stability of this compound class. Therefore, we synthesized a series of novel derivatives to investigate the influence of the electron-donating properties of methyl substituents at the

SUBMITTER: Mathuber M 

PROVIDER: S-EPMC7724630 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature